Bridge Creek Capital Management LLC boosted its stake in Merck & Company, Inc. (NYSE:MRK) by 10.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,323 shares of the company’s stock after buying an additional 400 shares during the period. Bridge Creek Capital Management LLC’s holdings in Merck & were worth $275,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRK. LaFleur & Godfrey LLC purchased a new position in Merck & during the first quarter valued at about $15,250,000. Sumitomo Mitsui Asset Management Company LTD increased its position in Merck & by 8.2% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 329,953 shares of the company’s stock valued at $20,965,000 after buying an additional 24,937 shares during the period. Essex Investment Management Co. LLC purchased a new position in Merck & during the first quarter valued at about $757,000. Agran Libbie increased its position in Merck & by 83.0% in the first quarter. Agran Libbie now owns 11,918 shares of the company’s stock valued at $757,000 after buying an additional 5,404 shares during the period. Finally, Vigilant Capital Management LLC increased its position in Merck & by 16.7% in the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after buying an additional 250 shares during the period. 73.46% of the stock is owned by institutional investors and hedge funds.
Merck & Company, Inc. (MRK) traded down 0.57% during midday trading on Friday, hitting $61.49. The company had a trading volume of 8,421,689 shares. Merck & Company, Inc. has a one year low of $58.29 and a one year high of $66.80. The company’s 50 day moving average is $62.91 and its 200-day moving average is $63.83. The company has a market cap of $167.71 billion, a P/E ratio of 33.29 and a beta of 0.80.
Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The company had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. During the same quarter last year, the firm earned $0.93 EPS. Merck &’s revenue for the quarter was up .9% compared to the same quarter last year. On average, equities analysts predict that Merck & Company, Inc. will post $3.87 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 3.06%. The ex-dividend date is Thursday, September 14th. Merck &’s payout ratio is presently 76.11%.
WARNING: This article was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/bridge-creek-capital-management-llc-buys-400-shares-of-merck-co-inc-mrk-updated-updated-updated.html.
Several research analysts recently weighed in on MRK shares. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $74.00 target price (up previously from $70.00) on shares of Merck & in a research note on Thursday, July 27th. Citigroup Inc. set a $65.00 price objective on shares of Merck & and gave the company a “hold” rating in a research note on Wednesday, July 5th. Zacks Investment Research raised shares of Merck & from a “hold” rating to a “buy” rating and set a $73.00 price objective for the company in a research note on Friday, May 26th. BidaskClub downgraded shares of Merck & from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Finally, Piper Jaffray Companies set a $70.00 price objective on shares of Merck & and gave the company a “buy” rating in a research note on Saturday, July 29th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $69.58.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.